All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Join our
Treating classical Hodgkin lymphoma: Spotlight on targeted therapies
with Gilles Salles, Paul Bröckelmann, and Ann S. LaCasce
Saturday, November 2, 2024
8:50-9:50 CET
This independent educational activity is sponsored by Takeda. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. View funders.
The United States (US) Food & Drug Administration (FDA) have granted accelerated approval to polatuzumab vedotin (Pola) in combination with bendamustine (B) and rituximab (R) (BR) for the treatment of patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who are not eligible for transplant. This is the first chemoimmunotherapy to be approved in this setting.1,2
Pola is an antibody-drug conjugate which binds to CD79b on B-cells, specifically delivering a cytotoxic dose of monomethyl auristatin E (MMAE), which is a microtubule inhibitor.2,3 CD79b is a viable target in DLBCL as it is ubiquitously expressed in mature B-cell lymphomas.3
The phase Ib/II randomized trial compared Pola + BR to BR. Another arm of this trial investigated Pola + B + obinutuzumab (Pola + BG) to BG. The FDA approval is based on the results of the randomized phase Ib/II results presented at ASCO 20184 and ASH 20182 which are summarized below.
Results given as Pola + BR versus BR
|
Pola + BR |
BR |
Hazard ratio (HR) |
P value |
---|---|---|---|---|
Complete response rate |
40% |
18% |
- |
0.026 |
Median duration of response (DoR) |
10.3 months (5.6–not reached [NR]) |
4.1 months (2.6–12.7) |
0.44
|
0.032 |
Median progression-free survival (PFS) |
7.6 months (6.0–17.0) |
2.0 months (1.5–3.7) |
0.34
|
<0.0001 |
Median overall survival (OS) |
12.4 months (9.0–NR) |
4.7 months (3.7–8.3) |
0.42
|
0.0023 |
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Your opinion matters
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox